이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

이식 불가능한 신규 진단 다발성 골수종 환자에서 HLX15-SC와 DARZALEX FASPRO®를 레날리도마이드 및 덱사메타손(Rd)과 병용 투여 시 약동학적 특성, 안전성, 내약성 및 면역원성 비교 연구

2026년 9월 21일 업데이트: Shanghai Henlius Biotech

이식 불가능한 신규 진단 다발성 골수종 환자에서 HLX15-SC와 DARZALEX FASPRO®을 레날리도마이드 및 덱사메타손(Rd)과 병용 투여 시 약동학적 특성, 안전성, 내약성 및 면역원성을 비교하는 무작위, 이중 맹검, 병렬 대조군 1상 연구

The purpose of this study is to compare the pharmacokinetic (PK) similarity, safety, tolerability, immunogenicity, and efficacy of HLX15-SC versus US-DARZALEX FASPRO® following single and multiple subcutaneous (SC) injections in newly diagnosed MM patients ineligible for transplant.

Participants who meet all inclusion criteria and none of the exclusion criteria will receive either the HLX15-SC-Rd regimen or the D-Rd regimen for 4 cycles (one cycle = 4 weeks). After 4 cycles of treatment, based on clinical benefit and participant preference, participants may continue to receive the locally marketed daratumumab subcutaneous formulation (Dara-SC) in combination with Rd according to clinical practice, up to 32 weeks or until loss of clinical benefit, death, unacceptable toxicity, withdrawal of informed consent, or any other protocol-specified reason, whichever occurs first. After 32 weeks of dosing, participants will continue to receive appropriate standard of care according to local guidelines (including marketed Dara-SC).

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

258

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

  • 그루지야
      • Tbilisi, 그루지야, 0159
        • 아직 모집하지 않음
        • JSC K. Eristavi National Center of Experimental and Clinical Surgery
      • Tbilisi, 그루지야, 0160
        • 아직 모집하지 않음
        • LLC Caucasus Medical Centre
  • 미국
    • Arkansas
      • Springdale, Arkansas, 미국, 72762
        • 모병
        • Highlands Oncology Group, PA
    • Florida
      • Jacksonville, Florida, 미국, 32256
        • 모병
        • Cancer Specialists of North Florida
      • Margate, Florida, 미국, 33063
        • 모병
        • D&H National Research Center
      • Ocala, Florida, 미국, 34474
        • 모병
        • Ocala Oncology Center
      • Plantation, Florida, 미국, 33322
        • 모병
        • Florida Clinical Trials Group
      • Tamarac, Florida, 미국, 33321
        • 모병
        • Florida Clinical Trials Group
    • Indiana
      • Dyer, Indiana, 미국, 46311
        • 모병
        • Genesis Medical Research
    • Louisiana
      • Covington, Louisiana, 미국, 70433
        • 모병
        • Pontchartrain Cancer Center
    • Texas
      • Houston, Texas, 미국, 77030
        • 모병
        • Oncology Consultants (P1 Trials -Exigent Network)
      • Houston, Texas, 미국, 77090
        • 모병
        • Lumi Research
    • Washington
      • Everett, Washington, 미국, 98201
        • 모병
        • Optum Care Washington
      • Olympia, Washington, 미국, 98506
        • 모병
        • American Oncology Network Vista Oncology Division / Physician partner associate
  • 세르비아
      • Belgrade, 세르비아, 11080
        • 아직 모집하지 않음
        • Clinical Hospital Centre Zemun
      • Kragujevac, 세르비아, 34000
        • 아직 모집하지 않음
        • University Clinical Center Kragujevac
      • Niš, 세르비아, 8000
        • 아직 모집하지 않음
        • University Clinical Center Nis
  • 중국
    • Anhui
      • Bengbu, Anhui, 중국, 233000
        • 모병
        • The First Affiliated Hospital of Bengbu Medical University
      • Hefei, Anhui, 중국, 230601
        • 모병
        • The Second Affiliated Hospital of Anhui Medical University
      • Hefei, Anhui, 중국, 230031
        • 모병
        • Anhui Provincial Cancer Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100191
        • 모병
        • Peking University Third Hospital
      • Beijing, Beijing Municipality, 중국, 100035
        • 모병
        • Peking University First Hospital
      • Beijing, Beijing Municipality, 중국, 100027
        • 모병
        • Beijing Chao-Yang Hospital Capital Medical University
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, 중국, 400016
        • 모병
        • The First Affiliated Hospital of Chongqing Medical University
    • Fujian
      • Fuzhou, Fujian, 중국, 350004
        • 모병
        • The First Affiliated Hospital of Fujian Medical University
      • Xiamen, Fujian, 중국, 361001
        • 모병
        • The First Affiliated Hospital of Xiamen University
    • Guangdong
      • Guangzhou, Guangdong, 중국, 510080
        • 모병
        • Guangdong General Hospital
      • Guangzhou, Guangdong, 중국, 510013
        • 모병
        • Guangzhou First People's Hospital
      • Guangzhou, Guangdong, 중국, 510220
        • 모병
        • Zhujiang Hospital of Southern Medical University
      • Meizhou, Guangdong, 중국, 514031
        • 모병
        • Meizhou People's Hospital
      • Shenzhen, Guangdong, 중국, 518020
        • 모병
        • Shenzhen People's Hospital
      • Shenzhen, Guangdong, 중국, 518036
        • 모병
        • Peking University Shenzhen Hospital
    • Guangxi
      • Liuzhou, Guangxi, 중국, 545007
        • 모병
        • Liuzhou Worker's Hospital
      • Nanning, Guangxi, 중국, 530213
        • 모병
        • Guangxi Medical University Cancer Hospital
    • Guizhou
      • Guiyang, Guizhou, 중국, 550004
        • 모병
        • The Affiliated Hospital of Guizhou Medical University
    • Hebei
      • Baoding, Hebei, 중국, 071030
        • 모병
        • Affiliated Hospital of Hebei University
      • Cangzhou, Hebei, 중국, 061000
        • 모병
        • Cangzhou People's Hospital
      • Shijiazhuang, Hebei, 중국, 050071
        • 모병
        • The Second Hospital of Hebei Medical Universit
      • Shijiazhuang, Hebei, 중국, 050052
        • 모병
        • Hebei medical university third hospital
    • Heilongjiang
      • Harbin, Heilongjiang, 중국, 150069
        • 모병
        • Harbin Medical University Cancer Hospital
    • Henan
      • Luoyang, Henan, 중국, 471003
        • 모병
        • The First Affiliated Hospital of Henan University of Science & Techinology
      • Xinxiang, Henan, 중국, 453000
        • 모병
        • Xinxiang Central Hospital
      • Zhengzhou, Henan, 중국, 450003
        • 모병
        • Henan Cancer Hospital
      • Zhengzhou, Henan, 중국, 450052
        • 모병
        • The First Affiliated Hospital of Zhengzhou University
      • Zhengzhou, Henan, 중국, 450003
        • 모병
        • Henan Provincial People's Hospital
    • Hubei
      • Wuhan, Hubei, 중국, 430071
        • 모병
        • Zhongnan Hospital of Wuhan University
      • Wuhan, Hubei, 중국, 430061
        • 모병
        • Renmin Hospital of Wuhan University
      • Wuhan, Hubei, 중국, 430014
        • 모병
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Wuhan, Hubei, 중국, 430030
        • 모병
        • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
    • Hunan
      • Changsha, Hunan, 중국, 410011
        • 모병
        • The Second Xiangya Hospital of Central South University
      • Hengyang, Hunan, 중국, 421001
        • 모병
        • The First Affiliated Hospital Of University South China
    • Inner Mongolia
      • Hohhot, Inner Mongolia, 중국, 010030
        • 모병
        • The Affiliated Hospital of Inner Mongolia Medical University
    • Jangxi
      • Nanchang, Jangxi, 중국, 330008
        • 모병
        • The First Affiliated Hospital of Nanchang University
      • Nanchang, Jangxi, 중국, 330008
        • 모병
        • The second affiliated hospital of Nanchang University
    • Jiangsu
      • Nanjing, Jiangsu, 중국, 210009
        • 모병
        • Zhongda Hospital Southeast University
      • Nanjing, Jiangsu, 중국, 211166
        • 모병
        • Sir Run Run Hospital of Nanjing Medical University
      • Suzhou, Jiangsu, 중국, 215004
        • 모병
        • Nuclear Industry General Hospital (The Second Affiliated Hospital of Soochow University)
      • Wuxi, Jiangsu, 중국, 214000
        • 모병
        • Affiliated Hospital of Jiangnan University
      • Xuzhou, Jiangsu, 중국, 221006
        • 모병
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Ganzhou, Jiangxi, 중국, 341000
        • 모병
        • First Affiliated Hospital of Gannan Medical University
      • Nanchang, Jiangxi, 중국, 330029
        • 모병
        • Jiangxi Cancer Hospital
    • Liaoning
      • Dalian, Liaoning, 중국, 116001
        • 모병
        • Affiliated Zhongshan Hospital of Dalian University
      • Shenyang, Liaoning, 중국, 110004
        • 모병
        • Shengjing Hospital of China Medical University
      • Shenyang, Liaoning, 중국, 110001
        • 모병
        • The First Hospital of China Medical University
      • Shenyang, Liaoning, 중국, 110041
        • 모병
        • Liaoning Cancer Hospital & Institute
    • Shandong
      • Jinan, Shandong, 중국, 250022
        • 모병
        • Shandong Provincial Hospital
      • Jining, Shandong, 중국, 272000
        • 모병
        • Jining No.1 People's Hospital
      • Qingdao, Shandong, 중국, 266001
        • 모병
        • The Affiliated Hospital of Qingdao University
      • Weifang, Shandong, 중국, 261041
        • 모병
        • Weifang People's Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, 중국, 200032
        • 모병
        • Zhongshan Hospital, Fudan University
    • Shanxi
      • Taiyuan, Shanxi, 중국, 030001
        • 모병
        • The Second Hospital of Shanxi Medical University
      • Taiyuan, Shanxi, 중국, 030013
        • 모병
        • Shanxi Cancer Hospital
    • Sichuan
      • Chengdu, Sichuan, 중국, 610041
        • 모병
        • Sichuan Cancer Hospital
      • Chengdu, Sichuan, 중국, 610073
        • 모병
        • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, 중국, 300060
        • 모병
        • Tianjin Medical University Cancer Institute & Hospital
      • Tianjin, Tianjin Municipality, 중국, 300308
        • 모병
        • Tianjin Cancer Hospital Airport Hospital
      • Tianjin, Tianjin Municipality, 중국, 300131
        • 모병
        • Tianjin People's Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310006
        • 모병
        • Hangzhou First People's Hospital
      • Hangzhou, Zhejiang, 중국, 310015
        • 모병
        • Zhejiang Provincial People's Hospital
      • Hangzhou, Zhejiang, 중국, 310016
        • 모병
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine（The Grand Canal Campus）
      • Hangzhou, Zhejiang, 중국, 310020
        • 모병
        • The First Affiliated Hospital, Zhejiang University School of Medicine
      • Ningbo, Zhejiang, 중국, 315010
        • 모병
        • The First Affiliated Hospital of Ningbo University
      • Wenzhou, Zhejiang, 중국, 325000
        • 모병
        • The Second Affiliated Hospital of Wenzhou Medical University
  • 호주
      • Perth, 호주, 6005
        • 모병
        • Perth Blood Institute

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Age ≥ 18 years at the time of signing the informed consent form (ICF).

  2. Body mass index (BMI): 18.5 kg/m2 ≤ BMI < 28 kg/m2.

  3. Subjects must participate voluntarily, understand the study, and sign the ICF.

  4. Patients must have a documented diagnosis of multiple myeloma (MM) according to the International Myeloma Working Group (IMWG) criteria, with measurable lesion .

  5. Serum albumin ≥ 35 g/L.

  6. Newly diagnosed, untreated, and considered ineligible for high-dose chemotherapy with autologous stem cell transplantation (ASCT) by the investigator.

  7. The patient's ECOG performance status must be 0 or 1 .

  8. Patient must have clinical laboratory values meeting the following criteria during the screening period:

    1. Hemoglobin ≥ 7.5 g/dL (≥ 5 mmol/L; red blood cell [RBC] transfusion or use of recombinant human erythropoietin at least 1 week prior to randomization is allowed).
    2. Absolute neutrophil count (ANC) ≥ 1.0 × 109/L (use of granulocyte-colony stimulating factor [G-CSF] is allowed).
    3. Alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN).
    4. Without the following evidence of impaired liver function, including mild impairment (total bilirubin ≤ ULN and AST > ULN or ULN < total bilirubin ≤ 1.5 x ULN), moderate impairment (1.5 x ULN < total bilirubin ≤ 3 x ULN), and severe impairment (total bilirubin > 3 x ULN).
    5. Measured creatinine clearance ≥ 40 mL/min .
    6. Corrected serum calcium < 14 mg/dL (< 3.5 mmol/L); or free ionized calcium < 6.5 mg/dL (< 1.6 mmol/L) .
    7. Platelet count ≥ 70 × 109/L for patients with plasma cells < 50% of bone marrow nucleated cells; platelet count > 50 × 109/L for all other patients (transfusion within 3 days prior to randomization to achieve the minimum platelet count is not permitted).

  9. Contraceptive criteria: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Female patients: a female patient is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

      Not a woman of childbearing potential (WOCBP) or WOCBP: must commit to either abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously from signed ICF to at least 140 days following the last dose of study products. This includes one highly effective contraceptive method with a failure rate of < 1% per year (tubal ligation, intrauterine device, hormonal [birth control pills, injections, hormonal patches, vaginal rings or implants] or partner's vasectomy) and one additional effective contraceptive method (male latex or synthetic condom, diaphragm, or cervical cap). Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy or bilateral oophorectomy.

      The subjects also need to agree not to donate or cryopreservation eggs (ova, oocytes) from signed ICF to at least 140 days following the last dose of study products.

    2. Male patients: male patients are eligible to participate if they agree to the following during the intervention period and for at least 140 days following the last dose of study products:

    Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.

    or Agree to use a male condom and female partner to use an additional highly effective contraceptive method with a failure rate of <1% per year as when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.

    Agree not to donate or cryopreservation sperm.

  10. A WOCBP must have a negative serum pregnancy test at screening within 72 h prior to randomization. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy

Exclusion Criteria:

  1. Patient has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), Waldenström's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.

  2. Patient has plasma cell leukemia (according to IMWG criterion: ≥ 5% of plasma cells in the peripheral blood and/or an absolute plasma cell count of ≥ 2 x 109/L) or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).

  3. Patient has prior or current systemic therapy or ASCT for MM, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before randomization.

  4. Patient has peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.

  5. Patient has a history of malignancy (other than MM) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator is considered cured with minimal risk of recurrence within 3 years).

  6. Patient has clinical signs of meningeal involvement of MM.

  7. Patient has known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume in 1 second [FEV1] < 50% of predicted normal), persistent asthma, or a history of asthma within the last 2 years. Patient with known or suspected COPD or asthma must have a FEV1 test during screening.

  8. Patient is known to be seropositive for history of human immunodeficiency virus (HIV) or known to have treponema pallidum antibodies (Anti-TP).

  9. Patient is known to have active hepatitis B or C.

    1. Patient is seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Patients with resolved infection (that is, patients who are HBsAg negative but positive for antibodies to hepatitis B core antigen [Anti-HBc] and/or antibodies to hepatitis B surface antigen [Anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded.

      EXCEPTION: Patients with serologic findings suggestive of HBV vaccination (Anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.

    2. Patient is seropositive for hepatitis C must be screened using PCR measurement of hepatitis C virus (HCV) ribonucleic acid (RNA) levels. Those who are PCR positive will be excluded.

  10. Patient has any concurrent medical or psychiatric condition or disease (e.g., active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study.

  11. Patient has clinically significant cardiac disease, including:

    1. Myocardial infarction within 1 year before randomization, or an unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association [NYHA] Class III-IV ).
    2. Cardiac arrhythmia (NCI-CTCAE Version 6 Grade ≥ 2) or clinically significant ECG abnormalities.
    3. Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) (See Appendix 6) > 470 ms.

  12. Patient has known allergies, hypersensitivity, or intolerance to lenalidomide, corticosteroids, monoclonal antibodies or human proteins, or their excipients or known sensitivity to mammalian-derived products.

  13. Patient has history of drug abuse or substance abuse one year prior to randomization. Patient is known or suspected of not being able to comply with the study protocol (e.g., because of alcoholism, drug dependency, or psychological disorder).

  14. Patient is a woman who is pregnant, or breast-feeding, or planning to become pregnant or donate eggs (ova, oocytes) while enrolled in this study or within 140 days after the last dose of study products.

    Or patient is a man who plans to father a child and/or donate sperm while enrolled in this study or within 140 days after the last dose of study products.

    Patient does not agree to abstain completely from sexual intercourse, or plan to use a contraceptive method that is not acceptable to the investigator (unacceptable methods of contraception include: i. periodic abstinence [such as calendar method, ovulation method, basal body temperature method, post-ovulation safety period method, etc.], withdrawal, etc.; ii. medical contraceptive measures such as oral contraceptives, contraceptive injections, contraceptive patches, subcutaneous implantation, intrauterine hormone contraceptive devices, local contraceptives such as spermicides, etc.).

  15. Patient had radiation therapy within 14 days of randomization.

  16. Patient had plasmapheresis within 28 days of randomization.

  17. Patient had a history of blood donation or total blood loss of 200 mL or more within 3 months before randomization.

  18. Patient had major surgery within 28 days before randomization or has not fully recovered from surgery, or has surgery planned during the time the patient is expected to participate in the study or within 28 days after the last dose of study treatment. Kyphoplasty is not considered major surgery.

  19. Patient in clinical trials of any other drug or device within 3 months (or 5 half-lives of the corresponding investigational product if the half-life of the drug is long [5 half-lives > 3 months]) before randomization.

  20. Patient has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: HLX15-SC-Rd

HLX15-SC-Rd
의약품: HLX15-SC-Rd

Subjects will receive 1800 mg HLX15-SC via SC administration for up to 16 weeks: weekly during Week 1-8 (Cycle 1-2; 1 cycle = 4 weeks) and every two weeks during Week 9-16 (Cycle 3-4).
활성 비교기: US-DARZALEX FASPRO®-Rd

US-DARZALEX FASPRO®-Rd
의약품: US-DARZALEX FASPRO®-Rd

Subjects will receive 1800 mg US-DARZALEX FASPRO® via SC administration for up to 16 weeks: weekly during Week 1-8 (Cycle 1-2; 1 cycle = 4 weeks) and every two weeks during Week 9-16 (Cycle 3-4).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
pharmacokinetic (PK) similarity
기간: 7 days

Area under the serum concentration-time curve from time 0 to day 7 (AUC0-7d) after the 1st dose.
7 days
pharmacokinetic (PK) similarity
기간: 7 days

The maximum (peak) serum drug concentration (Cmax) after the 1st dose.
7 days
pharmacokinetic (PK) similarity
기간: 16 weeks

Area under the serum concentration-time curve within a dosing interval at steady-state (AUCss) after the 12th dose
16 weeks
pharmacokinetic (PK) similarity
기간: 16 weeks

The maximum (peak) serum drug concentration at steady-state (Cmax,ss) after the 12th dose
16 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
PK characteristics
기간: 16 weeks

trough concentration (Ctrough)
16 weeks
PK characteristics
기간: 16 weeks

trough concentration at steady state (Ctrough,ss).
16 weeks
Safety: Adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)
기간: 16 weeks

Adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) terms and frequency of occurrence judged by investigators
16 weeks
Safety: Vital Signs
기간: 16 weeks

Vital Signs: including blood pressure (systolic and diastolic; mmHg) , pulse rate (beats/min) measured by hematomanometer
16 weeks
Safety: Vital Signs
기간: 16 weeks

including body temperature (°C) measured by clinical thermometer
16 weeks
Safety: Physical examinations
기간: 16 weeks

Physical examinations: includes general condition; head and neck; mucous membranes; chest; abdomen; spine; extremities; musculoskeletal system; neurological system; lymphatic system; and skin checked by investigators
16 weeks
Safety: Laboratory tests
기간: 16 weeks

Laboratory tests: include hematology, blood chemistry, and urinalysis measured by the department of medical laboratory in site
16 weeks
Safety: Electrocardiography
기간: 16 weeks

Electrocardiography: 12-lead ECG will be performed by qualified personnel using an ECG machine, includes heart rate（beats per minute ）
16 weeks
Safety: Electrocardiography
기간: 16 weeks

Electrocardiography: 12-lead ECG will be performed by qualified personnel using an ECG machine, includes PR interval（msec）.
16 weeks
Safety: Electrocardiography
기간: 16 weeks

Electrocardiography: 12-lead ECG will be performed by qualified personnel using an ECG machine, includes QRS duration (msec).
16 weeks
Safety: Electrocardiography
기간: 16 weeks

Electrocardiography: 12-lead ECG will be performed by qualified personnel using an ECG machine, includes QTc interval (msec).
16 weeks
Immunogenicity:
기간: 16 weeks

Incidence of anti-drug antibodies (ADA) and neutralizing antibodies (NAb) against the study products (HLX15-SC and US-DARZALEX FASPRO®) and hyaluronidase.
16 weeks
Efficacy:ORR
기간: 16 weeks

Investigator-assessed overall response rate (ORR): is defined as the percentage of all patients achieving a PR or better after the randomization date.
16 weeks
Efficacy: partial response (PR) rate
기간: 16 weeks

Partial response (PR) rate is defined as the percentage of all patients achieving a PR at any time point after the randomization date
16 weeks
Efficacy: very good partial response (VGPR) rate
기간: 16 weeks

Very good partial response (VGPR) rate is defined as the percentage of all patients achieving a VGPR at any time point after the randomization date.
16 weeks
Efficacy: complete response (CR) rate
기간: 16 weeks

Complete response (CR) rate is defined as the percentage of all patients achieving a CR at any time point after the randomization date.
16 weeks
Efficacy: stringent complete response (sCR) rate
기간: 16 weeks

Stringent complete response (sCR) rate is defined as the percentage of all patients achieving an sCR at any time point after the randomization date.
16 weeks
Efficacy: time to response
기간: 16 weeks

Time to Response (TTR) is defined as the time from randomization to the first documented response of PR or better. TTR will be analyzed only for patients who achieve a response of PR or better.
16 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Shanghai Henlius Biotech

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 5월 25일

기본 완료 (추정된)

2027년 5월 25일

연구 완료 (추정된)

2028년 2월 22일

연구 등록 날짜

최초 제출

2026년 2월 27일

QC 기준을 충족하는 최초 제출

2026년 3월 12일

처음 게시됨 (실제)

2026년 3월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 21일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • HLX15-SC-NDMM-001

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다